Siemens Healthineers — Gartley Completion at Historical OBSiemens Healthineers is currently trading inside a technically important reaction zone on the daily chart.
The core element of this setup is a clearly developed bullish Gartley pattern. What makes the structure particularly relevant is its origin: the pattern begins at the historical low and therefore incorporates one of the most important long-term reference points visible on the chart.
After the corrective decline from the previous swing high, price has now reached the projected Gartley completion area and has already shown an initial reaction from the Potential Reversal Zone.
Gartley Completion Zone
The central Gartley completion level is located around 32.70 EUR.
This area corresponds to the 78.6% retracement of the original XA leg and represents the primary Point D projection of the pattern. Price has reacted from this zone and is currently attempting to stabilize above it.
The broader Gartley PRZ extends below the central completion level. This is important because harmonic reversal zones should not be interpreted as one exact price, but as a technical area in which a reversal structure may develop gradually.
Historical Order Block Confluence
The strongest structural confluence is located slightly below the Gartley completion level.
The Order Block around 28.50–30.00 EUR originates from the historical low that also forms the starting point of the Gartley pattern. This gives the zone additional technical relevance.
The setup therefore combines:
* A clearly developed bullish Gartley pattern
* A Point D completion near 32.70 EUR
* A long-term Order Block derived from the historical low
* A potential exhaustion area after the previous corrective decline
The Gartley completion zone provides the first reaction area. The historical Order Block acts as a deeper support layer if price retests the lower part of the PRZ before a sustainable recovery develops.
Expected Scenario
The preferred scenario is a stabilization above the Gartley Point D area, followed by a gradual recovery toward the Fibonacci retracement targets above.
The first major objective is the 38.2% retracement near 42.34 EUR.
If the recovery develops with sufficient strength and forms a constructive higher-low structure, the next upside targets are:
* TP1: 42.34 EUR
* TP2: 48.28 EUR
* TP3: 52.50 EUR
* TP4: 57.89 EUR
A temporary retest of the lower PRZ remains possible. Such a move would not automatically invalidate the bullish scenario, especially if buyers react inside the historical Order Block.
Invalidation
The bullish recovery scenario becomes weaker if price loses the lower boundary of the Gartley PRZ and fails to react from the historical Order Block.
The deeper invalidation level is located below approximately 27.86 EUR.
A sustained move below this area would indicate that the long-term support structure has failed and that the Gartley reversal scenario is no longer valid.
Conclusion
Siemens Healthineers has completed a well-defined bullish Gartley pattern whose structure begins at the historical low.
The confluence between the Gartley PRZ and the historical Order Block creates a technically relevant support area between approximately 28.50 and 32.70 EUR. The initial reaction from Point D is constructive, but the market still needs to confirm that buyers can stabilize price above this support structure.
As long as the broader PRZ remains intact, a recovery toward the first Fibonacci target near 42.34 EUR remains the preferred scenario.
Siemens Healthineers AG
No trades
No trades
In-depth trading ideas
SHLSiemens Healthineers is a German company which provides healthcare services. It was spun off from its parent company Siemens in 2017, which retains a 75% stake. Siemens Healthineers is the parent company for several medical technology companies and is headquartered in Erlangen, Germany.
A name via my screen. An appealing medium term structure.
Siemens Healthineers: Not yet done ☝️Siemens Healthineers took a step south at the beginning of the year, but has since almost made up for this setback on the upside. Nevertheless, we have drawn up a new alternative scenario with a 30% probability on the chart, according to which the current rise would already be completed with the last high in the form of the magenta-colored wave alt.(X). Accordingly, the price would fall below the support level of €45.51 earlier and consequently into our turquoise-colored Target Zone between €40.32 and €36.13. As part of our primary scenario, however, we give the stock a little more room on the upside - namely until just above the resistance at €53.98 - in order to underpin the top of the regular magenta-colored wave (x). Only then should it dive into the turquoise Target Zone.
Operación en largo sobre SHLXETR:SHL
Operación de entrada en largo sobre SHL tras la rotura del rectángulo de acumulación tras la corrección al 61.8 Fibo.
Paciencia y esperar a que rompa y cierre en diario por encima de 38.9
Resistencias: 41.7 - 45.63 - 47.2
Stop en 35.5
Objetivo mínimo 45.63, coinciente con la 1º resistencia.
Recomendación: Ir ajustano el stop mejor que colocar un takeprofit.
SHL Siemens potential path into Germany’s benchmark DAX30 indexThe $16.4 billion purchase of Varian Medical Systems not only gives Siemens Healthineers AG an entry into cancer treatment -- one of the hottest areas in medical technology -- but also opens a potential path into Germany’s benchmark DAX index.
“We’ll create additional free float which eventually will lift us into the DAX,” Chief Executive Officer Bernd Montag said in an interview with Bloomberg TV. “We are very certain about this transaction, it’s the right time, and we are super confident about financing.”
The Erlangen, Germany-based maker of MRI machines and laboratory equipment announced Sunday it’s offering $177.50 a share for Palo Alto, California-based Varian, 24% more than its closing price on Friday. Bloomberg was first to report the offer on Saturday.
With Varian, Healthineers will gain market share in devices and software used for cancer therapy. Recent developments in radiation therapy, coupled with more precise imaging, have been linked to lower cancer death rates, which Montag said the company is keen to capitalize on.
The deal has “clear strategic rationale,” Citigroup analyst Kate Kalashnikova said in a note. “The combined company will have the most comprehensive cancer portfolio in the industry.”
The deal is the biggest health-care acquisition this year.
Source: Bloomberg
If you are interested to test some amazing buy and sell indicators, which give the signal at the beginning of the candle, not at the end of it, just leave me a message.






